Estrogen Delivery Methods and Clot Risk

When women discuss HRT, the conversation often centres on whether to take it at all. Less discussed is that how you take estrogen matters clinically, not just for convenience. The route of delivery affects how estrogen is metabolized, its clot risk profile, and how stable your levels will be day to day.

Current UK and US guidelines recommend transdermal estrogen as preferred for most women, particularly those with cardiovascular or clotting risk factors.[1][2] Understanding why can help you have a more useful conversation with your doctor.

First-Pass Metabolism: Why the Liver Matters

When you swallow an oral estrogen tablet, it is absorbed from the gut and passes directly to the liver before entering general circulation. This is called first-pass hepatic metabolism, and it has consequences.[3]

The liver responds to a surge of estrogen by increasing production of several proteins:

• Clotting factors (factor VII, fibrinogen): increases blood coagulation
• Sex hormone-binding globulin (SHBG): binds to estrogen and reduces its biological availability
• C-reactive protein (CRP): elevated with oral estrogen
• Triglycerides: elevated with oral estrogen

None of these effects are necessarily dangerous in a healthy woman with no other risk factors. But they are relevant if you have risk factors for blood clots, cardiovascular disease, or migraines, and they represent unnecessary metabolic work when the same symptom control can be achieved without them.

Transdermal Estrogen Bypasses the Liver

Patches, gels, and sprays deliver estrogen through the skin directly into the bloodstream, bypassing the gut and liver. The estrogen that reaches circulation is essentially the same estradiol your ovaries would have made, metabolized the same way.[3]

The clinical differences are meaningful:

No increase in clotting factors. Multiple studies have found that transdermal estrogen does not increase the risk of venous thromboembolism (VTE), while oral estrogen is associated with a 2–4 fold increase.[4][5] The ESTHER study (2007) found that women using transdermal estrogen had no significantly increased VTE risk compared to non-users, while oral users had an odds ratio of 4.2.[4]

No increase in stroke risk. A large UK study using the Clinical Practice Research Datalink found no increased stroke risk with transdermal estrogen. Oral estrogen was associated with increased ischemic stroke risk in a dose-dependent manner.[6]

More stable blood levels. Oral estrogen creates peaks and troughs with each dose. Transdermal delivery (particularly patches) maintains more consistent estradiol levels throughout the day.[3]

The Three Transdermal Forms

Patches are the most studied transdermal form. Twice-weekly patches (changed on days 1 and 4 of each week) and weekly patches are both available. They deliver the most consistent estradiol levels and require the least day-to-day effort. Skin reactions at the adhesive site occur in a minority of users; rotating application sites helps.

Gels are applied daily to the arm, thigh, or abdomen. They are absorbed within a few minutes and invisible once dry. Gel allows dose adjustment in small increments, which some women find useful during perimenopause when needs fluctuate. The main practical consideration is avoiding skin-to-skin transfer to partners or children before the gel has fully absorbed.

Sprays work similarly to gels. A single pump delivers a metered dose to the forearm. Application is daily and requires a brief drying period.

The Progestogen Component

Women who still have a uterus need a progestogen alongside estrogen to protect the uterine lining from endometrial hyperplasia. The type of progestogen matters.

Micronized progesterone (Utrogestan in the UK, Prometrium in the US) is bioidentical to the progesterone the body makes. It has better tolerability than synthetic progestins for most women, with a profile of neutral or beneficial effects on mood, sleep, and potentially breast cancer risk.[7][8] It is taken orally at night (making use of its mild sedative effect) or vaginally.

Synthetic progestins (medroxyprogesterone acetate, norethisterone, levonorgestrel, dydrogesterone) are not the same molecule as natural progesterone and interact with receptors differently. MPA, used in the original WHI trial, has been associated with greater breast cancer risk in combined regimens than micronized progesterone.[7]

The Mirena IUS delivers levonorgestrel locally to the uterus with minimal systemic absorption. For women who want to combine uterine protection with low systemic progestogen exposure, it is an option worth discussing with a gynaecologist.

Practical Comparison

Method	Frequency	Liver effect	VTE risk	Level stability	Notes
Oral tablet	Daily	Yes	Increased	Peak/trough	Cheapest; avoid with clot risk
Twice-weekly patch	Every 3–4 days	No	Not increased	Good	Most studied; some skin reactions
Weekly patch	Weekly	No	Not increased	Very good	Convenient; fewer changes
Gel	Daily	No	Not increased	Good	Flexible dosing; requires drying time
Spray	Daily	No	Not increased	Good	Similar to gel; metered dose

Choosing a Formulation

The choice of delivery method should factor in:

• Personal and family history of blood clots: transdermal is strongly preferred
• Cardiovascular risk factors: transdermal is preferred
• Skin sensitivity: if patches cause reactions, gel or spray may suit better
• Adherence preferences: some women find a daily gel easier to remember; others prefer the twice-weekly patch routine
• Dose flexibility: gel allows easier adjustment for fluctuating needs in early perimenopause
• Progestogen preferences: if you have a uterus and want to minimize systemic progestogen exposure, the Mirena IUS combined with transdermal estrogen is worth considering

The goal is the formulation that best balances efficacy, safety for your specific risk profile, and likelihood of consistent use.

---

References

[1] NICE Guideline NG23. (2023). Menopause: Diagnosis and Management. National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/ng23

[2] The NAMS 2022 Hormone Therapy Position Statement Advisory Panel. (2022). The 2022 hormone therapy position statement of The Menopause Society. Menopause, 29(7), 767-794. https://doi.org/10.1097/GME.0000000000002028

[3] Stanczyk, F. Z., Bhavnani, B. R. (2014). Use of medroxyprogesterone acetate for hormone therapy in postmenopausal women: Is it safe? Journal of Steroid Biochemistry and Molecular Biology, 142, 30-38. https://doi.org/10.1016/j.jsbmb.2013.11.011

[4] Canonico, M., Oger, E., Plu-Bureau, G., et al. (2007). Hormone therapy and venous thromboembolism among postmenopausal women: Impact of the route of estrogen administration and progestogens. The ESTHER Study. Circulation, 115(7), 840-845. https://doi.org/10.1161/CIRCULATIONAHA.106.642280

[5] Sweetland, S., Beral, V., Balkwill, A., et al. (2012). Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. Journal of Thrombosis and Haemostasis, 10(11), 2277-2286. https://doi.org/10.1111/j.1538-7836.2012.04919.x

[6] Renoux, C., Dell’Aniello, S., Garbe, E., Suissa, S. (2010). Transdermal and oral hormone replacement therapy and the risk of stroke: A nested case-control study. BMJ, 340, c2519. https://doi.org/10.1136/bmj.c2519

[7] Fournier, A., Berrino, F., Clavel-Chapelon, F. (2008). Unequal risks for breast cancer associated with different hormone replacement therapies: Results from the E3N cohort study. Breast Cancer Research and Treatment, 107(1), 103-111. https://doi.org/10.1007/s10549-007-9523-x

[8] Schüssler, P., Kluge, M., Yassouridis, A., et al. (2008). Progesterone reduces wakefulness in sleep EEG and has no effect on cognition in healthy postmenopausal women. Psychoneuroendocrinology, 33(8), 1124-1131. https://doi.org/10.1016/j.psyneuen.2008.05.013